Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply195
Issue Information136
AP&T: Editors' Declarations of Interest120
Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification117
Issue Information111
105
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC86
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease82
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease79
77
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep74
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply69
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?65
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply64
Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease61
Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea59
Issue Information59
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis59
57
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease56
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC55
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted54
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply54
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B53
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply53
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough51
Editorial: Plants against animals51
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply51
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease51
Letter: Ozanimod and latent tuberculosis50
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply49
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply49
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension48
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score47
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?47
Editorial: Can we predict or not predict response to hypnotherapy? That is the question45
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply42
Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study41
Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment40
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply40
Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis40
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients40
Development of a model to identify patients who do not need oesophageal biopsies when eosinophilic oesophagitis is suspected40
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials40
1.3119530677795